Investors / RA Capital
RA Capital
Venture capital
RA Capital is an investment firm that funds and builds companies across healthcare, life sciences, and planetary health. It invests across public and private markets and creates new companies when needed, supported by a team of over 250 people.
Invests inHealthcare & Biotech
In its own wordshealthcarelife sciencesbiotechplanetary healthpublic marketscompany creation
Your fit with RA Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsRA Capital lists 216 checked portfolio companies on its own site and is named in 64 funding rounds, 25 of them as lead. Its most frequent entry is Growth, 39% of the companies with a known first round. Its largest themes are Healthcare & Biotech (86%), Industrial & Manufacturing (4%) and AI & Machine Learning (2%). 81% of its companies are based in United States. It invests most often alongside Foresite Capital, Frazier Life Sciences and Nextech Invest.
Counts come from funding rounds that name RA Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not RA Capital's whole history. Rounds on record name 63 companies; its own site lists 216. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 3% |
| Series A | 34% |
| Series B | 24% |
| Growth | 39% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 1 | 1 |
| '23 | 0 | 0 |
| '24 | 3 | 0 |
| '25 | 17 | 5 |
| '26 | 43 | 19 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 99th | 215 companies |
| Recent activity | 100th | 46 rounds in 12 months |
| Early stage | 54th | 3% of entries at pre-seed or seed |
| Evidence | 94th | 24% of companies confirmed by a round |
| Sector focus | 95th | 86% in its largest sector |
| Reach | 98th | 14 countries |
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 86% | 15% |
| Industrial & Manufacturing | 4% | 7% |
| AI & Machine Learning | 2% | 18% |
| Education | 2% | 7% |
| Real Estate & Construction | 1% | 3% |
| E-commerce & Marketplaces | 1% | 6% |
| Food & Agriculture | 1% | 3% |
| Fintech | 1% | 12% |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Foresite Capital | 21 |
| Frazier Life Sciences | 17 |
| Nextech Invest | 16 |
| Longitude Capital | 15 |
| Vivo Capital | 14 |
| Catalio Capital Management | 11 |
| NEA | 11 |
| Sanofi Ventures | 11 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers20193%
- No longer answers00%
- Points to another company157%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Foresite Capital
Compare RA Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with RA Capital| Date | Company | Stage |
|---|---|---|
| 9 Nov 2026 | Series C+ | |
| 5 Nov 2026 | Series A Led | |
| 23 Oct 2026 | Series C+ | |
| 21 Oct 2026 | Series A | |
| 16 Oct 2026 | Series A Led | |
| 16 Sept 2026 | Series C+ | |
| 15 Sept 2026 | Series B Led | |
| 9 Sept 2026 | Series A Led |
Round details for RA Capital
Amounts, full round histories and every co-investor in RA Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
216 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
Healthcare & Biotech | Portfolio page | |||
| Alpha-9 Oncology is a clinical stage radiopharmaceutical company advancing a portfolio of molecules to treat cancer cells | Healthcare & Biotech | Oct 2024Series C+ | Page + round | |
| Abcuro develops therapies for autoimmune diseases and cancer. | Healthcare & Biotech | Portfolio page | ||
| Aclaris Therapeutics is a biopharmaceutical company that strives to translate scientific discovery into everyday victories in immuno-inflammatory conditions. | Healthcare & Biotech | Portfolio page | ||
| Acrivon is developing targeted therapies to improve the lives of patients. | Healthcare & Biotech | Portfolio page | ||
| Acumen Pharmaceuticals is developing targeted Alzheimer's disease treatments | Healthcare & Biotech | Portfolio page | ||
| The company uses cookies to run its site and improve it | Healthcare & Biotech | Portfolio page | ||
| Adcendo is developing a new generation of antibody-drug conjugates to address cancers with high unmet medical need. | Healthcare & Biotech | Apr 2026Series C+ | Page + round | |
| Adcytherix is building an antibody-drug conjugate powerhouse to advance patient-need-driven therapies | Healthcare & Biotech | Oct 2025Series A | Page + round | |
Healthcare & Biotech | Portfolio page | |||
| Portfolio page | ||||
| Aktis Oncology develops targeted alpha-based radiopharmaceuticals for the treatment of cancer patients. | Healthcare & Biotech | Portfolio page | ||
| Alchemab Therapeutics develops antibody therapeutics for hard to treat diseases using the immune system | Healthcare & Biotech | Sept 2025Series A | Page + round | |
| Alentis Therapeutics is a clinical-stage biotech company that treats cancer and reverses fibrosis by developing anti-Claudin-1 antibody-drug conjugates and monoclonal antibodies | Healthcare & Biotech | Portfolio page | ||
| Alethio Therapeutics is developing therapies to improve outcomes for patients with myeloproliferative neoplasms, a group of blood cancers. | Healthcare & Biotech | Nov 2026Series A | Page + round | |
| Altrubio develops novel therapeutics for immunological diseases | Healthcare & Biotech | Portfolio page | ||
| AM Batteries manufactures lithium-ion battery electrodes using a dry coating process | Industrial & ManufacturingClimate & Energy | Portfolio page | ||
| Ambros Therapeutics is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases with a high unmet medical need. | Healthcare & Biotech | Dec 2025Series A | Page + round | |
| Amplifier Therapeutics doses patients in clinical trials and develops treatments for metabolic disease | Healthcare & Biotech | Portfolio page | ||
| AN2 Therapeutics develops boron-based medicines for various diseases, including polycythemia vera, Chagas disease, and certain types of cancer. | Healthcare & Biotech | Portfolio page |
About this data
site last read 10 Nov 2026- Site
- racap.com
- Last read
- 10 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 9 Feb 2022
- Companies checked
- 216
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get RA Capital's profile as data
Pull RA Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/racap.com
# also
GET /v1/firms/racap.com/portfolio
GET /v1/firms/racap.com/coinvestors
GET /v1/firms/racap.com/news